Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks.

MLA

Mastorino, L., et al. “Impact of Comorbidities in the Response of Atopic Patients Treated with Dupilumab: A Real‐life Study up to 36 Weeks.” Journal of the European Academy of Dermatology & Venereology, vol. 36, no. 12, Dec. 2022, pp. e1021–23. EBSCOhost, https://doi.org/10.1111/jdv.18427.

APA

Mastorino, L., Cantafio Duò, V. L., Vecco, C., Gelato, F., Giordano, S., Roccuzzo, G., Cavaliere, G., Avallone, G., Ortoncelli, M., Ribero, S., & Quaglino, P. (2022). Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks. Journal of the European Academy of Dermatology & Venereology, 36(12), e1021–e1023. https://doi.org/10.1111/jdv.18427

Chicago

Mastorino, L., V.L. Cantafio Duò, C. Vecco, F. Gelato, S. Giordano, G. Roccuzzo, G. Cavaliere, et al. 2022. “Impact of Comorbidities in the Response of Atopic Patients Treated with Dupilumab: A Real‐life Study up to 36 Weeks.” Journal of the European Academy of Dermatology & Venereology 36 (12): e1021–23. doi:10.1111/jdv.18427.